Prodotti competitors / Area Oncology 21 marzo 2025 FDA granted traditional approval to Keytruda for HER2+PD-L1+ gastric or GEJ adenocarcinoma
Prodotti competitors / Area Oncology 28 febbraio 2025 Enhertu (trastuzumab deruxtecan): CHMP opinion on variation to marketing authorisation in HR-positive HER2-low or -ultralow breast cancer
Prodotti competitors / Area Oncology 31 gennaio 2025 Positive CHMP Opinion for Datopotamab Deruxtecan (Datroway) for the 2L+ treatment of unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer
Prodotti competitors / Area Oncology 31 gennaio 2025 FDA approval for trastuzumab deruxtecan for adult patients with unresectable or metastatic HR positive, HER2-low or HER2-ultralow breast cancer
Prodotti competitors / Area Oncology 17 gennaio 2025 FDA approves datopotamab deruxtecan for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Prodotti competitors / Area Oncology 1 ottobre 2024 FDA granted priority review for T-DXd (Enhertu) for the treatment of HER2-low or HER2-ultralow mBC after at least one ET in the metastatic setting
Prodotti competitors / Area Oncology 24 settembre 2024 Datopotamab deruxtecan: final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
Prodotti competitors / Area Oncology 23 settembre 2024 Survival results for datopotamab deruxtecan in TROPION- Breast01 did not achieve statistical significance versus chemotherapy
Prodotti competitors / Area Oncology 23 settembre 2024 Datopotamab deruxtecan final overall survival results in patients with metastatic HR-positive, HER2-low or negative breast cancer did not achieve statistical significance versus chemotherapy
Prodotti competitors / Area Oncology 29 maggio 2024 NICE: nessuna raccomandazione per Trastuzumab deruxtecan per il trattamento del carcinoma polmonare non a piccole cellule avanzato HER2-mutato dopo chemioterapia a base di platino
